Mylan shares languish at low valuation as EpiPen hearing nears

NEW YORK (Reuters) - Shares of Mylan NV are trading at historically low valuations as the company's chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatment.

Mylan shares languish at low valuation as EpiPen hearing nears
Read More


Bagikan Berita Ini